A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

The Bruton tyrosine kinase inhibitor ibrutinib induces high rates of clinical response in chronic lymphocytic leukemia (CLL). However, there remains a need for adjunct treatments to deepen response and to overcome drug resistance. Blinatumomab, a CD19/CD3 bispecific antibody (bsAb) designed in the B...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Robinson, Hannah R., Qi, Junpeng, Cook, Erika M., Nichols, Cydney, Dadashian, Eman L., Underbayev, Chingiz, Herman, Sarah E. M., Saba, Nakhle S., Keyvanfar, Keyvan, Sun, Clare, Ahn, Inhye E., Baskar, Sivasubramanian, Rader, Christoph, Wiestner, Adrian
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073325/
https://ncbi.nlm.nih.gov/pubmed/29743179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-02-830992
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki